Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $161

Raymond James analyst Steven Seedhouse maintains Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and lowers the price target from $170 to $161.

Benzinga · 01/08/2020 14:05

Raymond James analyst Steven Seedhouse maintains Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and lowers the price target from $170 to $161.